MTSS1 has been characterized as a tumor suppressor in breast cancer [35] and chronic myeloid leukemia [36], however overexpression of MTSS1 has been observed in melanomas and hepatocellular carcinomas [37–39]. Here, MTSS1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.